MX2018009860A - Anticuerpos para il-17c. - Google Patents

Anticuerpos para il-17c.

Info

Publication number
MX2018009860A
MX2018009860A MX2018009860A MX2018009860A MX2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A
Authority
MX
Mexico
Prior art keywords
antibodies
antibody fragments
psoriasis
humans
human
Prior art date
Application number
MX2018009860A
Other languages
English (en)
Inventor
Klattig Jürgen
Ernest René Vandeghinste Nick
Dominik Haas Jan
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2018009860A publication Critical patent/MX2018009860A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos o fragmentos de anticuerpo que se unen a IL-17C humana. En particular, se refiere a anticuerpos o fragmentos de anticuerpo que tienen propiedades beneficiosas combinadas y por lo tanto, son útiles para el tratamiento de seres humanos que tienen, por ejemplo, dermatitis atópica o psoriasis.
MX2018009860A 2016-02-19 2017-02-17 Anticuerpos para il-17c. MX2018009860A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (en) 2016-02-19 2017-02-17 Antibodies for il-17c

Publications (1)

Publication Number Publication Date
MX2018009860A true MX2018009860A (es) 2019-03-28

Family

ID=58057136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009860A MX2018009860A (es) 2016-02-19 2017-02-17 Anticuerpos para il-17c.

Country Status (33)

Country Link
US (5) US20190048071A1 (es)
EP (1) EP3416983B1 (es)
JP (2) JP6535139B2 (es)
KR (1) KR102715157B1 (es)
CN (1) CN108699143B (es)
AU (1) AU2017219837B2 (es)
BR (1) BR112018016798A2 (es)
CA (1) CA3014842A1 (es)
CL (1) CL2018002340A1 (es)
CO (1) CO2018008724A2 (es)
CU (1) CU20180087A7 (es)
CY (1) CY1124296T1 (es)
DK (1) DK3416983T3 (es)
EA (1) EA037813B1 (es)
EC (1) ECSP18070641A (es)
ES (1) ES2877376T3 (es)
HR (1) HRP20211059T1 (es)
HU (1) HUE054755T2 (es)
IL (1) IL260733B2 (es)
LT (1) LT3416983T (es)
MA (2) MA44227B1 (es)
MD (1) MD3416983T2 (es)
MX (1) MX2018009860A (es)
PH (1) PH12018501739A1 (es)
PL (1) PL3416983T3 (es)
RS (1) RS62012B1 (es)
SG (1) SG11201806161TA (es)
SI (1) SI3416983T1 (es)
SM (1) SMT202100361T1 (es)
TN (1) TN2018000289A1 (es)
TW (1) TW201734041A (es)
WO (1) WO2017140831A1 (es)
ZA (1) ZA201806249B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060289A1 (en) * 2015-10-05 2017-04-13 Morphosys Ag Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
MA44227B1 (fr) * 2016-02-19 2021-06-30 Galapagos Nv Anticorps pour il-17c
TW201919698A (zh) * 2017-09-25 2019-06-01 德商莫菲西斯公司 異位性皮炎之治療
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
JP7780430B2 (ja) * 2019-11-22 2025-12-04 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング イオン交換クロマトグラフィー中に抗体収率を増加させるための方法
KR20220103967A (ko) * 2019-11-22 2022-07-25 모르포시스 아게 항체 크로마토그래피 동안의 용리액 수집

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
IL138930A0 (en) * 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
JP2008516985A (ja) 2004-10-18 2008-05-22 ザイモジェネティクス，インコーポレイティド 可溶性ｚｃｙｔｏｒ２１、抗ｚｃｙｔｏｒ２１抗体及び結合パートナー、並びに炎症における使用方法
CA2624763A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
CA2666842A1 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
WO2012061129A1 (en) * 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
DK2640742T3 (en) 2010-11-19 2018-12-03 Morphosys Ag COLLECTION OF ANTIBODY SEQUENCES AND THEIR APPLICATIONS
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
ES2669984T3 (es) * 2011-10-19 2018-05-29 Morphosys Ag Antagonistas de IL17C para el tratamiento de trastornos inflamatorios
ES2685553T3 (es) 2012-06-12 2018-10-09 Orega Biotech Antagonistas de isoformas de IL-17 y sus usos
CN107108728A (zh) * 2014-12-15 2017-08-29 莫佛塞斯公司 Il‑17c的抗体
MA44227B1 (fr) * 2016-02-19 2021-06-30 Galapagos Nv Anticorps pour il-17c

Also Published As

Publication number Publication date
MA44227B1 (fr) 2021-06-30
EA037813B1 (ru) 2021-05-24
MA43088A1 (fr) 2019-05-31
KR20180109977A (ko) 2018-10-08
CY1124296T1 (el) 2022-11-25
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
US10259869B2 (en) 2019-04-16
WO2017140831A1 (en) 2017-08-24
CL2018002340A1 (es) 2018-11-23
IL260733A (es) 2018-09-20
EP3416983B1 (en) 2021-04-07
US20180340024A1 (en) 2018-11-29
LT3416983T (lt) 2021-07-12
JP2019162119A (ja) 2019-09-26
IL260733B1 (en) 2023-11-01
IL260733B2 (en) 2024-03-01
KR102715157B1 (ko) 2024-10-10
JP2019511910A (ja) 2019-05-09
MA43088B1 (fr) 2020-10-28
US20250074978A1 (en) 2025-03-06
PH12018501739A1 (en) 2019-06-10
HUE054755T2 (hu) 2021-09-28
US20200216529A1 (en) 2020-07-09
JP6535139B2 (ja) 2019-06-26
CA3014842A1 (en) 2017-08-24
MA44227A (fr) 2018-12-26
MD3416983T2 (ro) 2021-08-31
TN2018000289A1 (en) 2020-01-16
TW201734041A (zh) 2017-10-01
RS62012B1 (sr) 2021-07-30
AU2017219837A1 (en) 2018-08-09
EA201891594A1 (ru) 2019-01-31
ZA201806249B (en) 2020-02-26
BR112018016798A2 (en) 2018-12-26
US20190048071A1 (en) 2019-02-14
SI3416983T1 (sl) 2021-08-31
HRP20211059T1 (hr) 2021-10-01
SG11201806161TA (en) 2018-08-30
PL3416983T3 (pl) 2021-10-25
ES2877376T3 (es) 2021-11-16
US11987621B2 (en) 2024-05-21
JP6916834B2 (ja) 2021-08-11
CN108699143B (zh) 2021-11-09
ECSP18070641A (es) 2018-10-31
CO2018008724A2 (es) 2018-08-31
SMT202100361T1 (it) 2021-07-12
US20190202906A1 (en) 2019-07-04
EP3416983A1 (en) 2018-12-26
US10633439B2 (en) 2020-04-28
AU2017219837B2 (en) 2023-08-17
DK3416983T3 (en) 2021-06-21

Similar Documents

Publication Publication Date Title
PH12018501739A1 (en) Antibodies for il-17c
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
ZA201905488B (en) Tigit- and light-based chimeric proteins
PH12019502283A1 (en) Anti-lag3 antibodies
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
MY198562A (en) Antibodies specifically binding pd-1 and their uses
EP4417263A3 (en) Cd3 binding antibodies
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MY186352A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
PH12016501820A1 (en) Il-21 antibodies
MX2022006573A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
ZA201807816B (en) Anti-il-22r antibodies
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
ZA202006216B (en) Antibodies targeting glycoprotein vi